RenovoRx logo

RenovoRxNASDAQ: RNXT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 August 2021

Next earnings report:

09 May 2025

Last dividends:

N/A

Next dividends:

N/A
$29.28 M
-54%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
76%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Thu, 21 Nov 2024 00:47:03 GMT
$1.22+$0.12(+10.91%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

RNXT Latest News

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
globenewswire.com25 September 2024 Sentiment: POSITIVE

Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
globenewswire.com19 September 2024 Sentiment: POSITIVE

Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
globenewswire.com14 August 2024 Sentiment: POSITIVE

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
globenewswire.com08 July 2024 Sentiment: POSITIVE

Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial
globenewswire.com26 June 2024 Sentiment: POSITIVE

Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
globenewswire.com10 June 2024 Sentiment: POSITIVE

New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology

RenovoRx CEO Issues Update Letter to Shareholders
businesswire.com30 May 2024 Sentiment: POSITIVE

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable.

RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
InvestorPlace08 April 2024 Sentiment: NEGATIVE

RenovoRx (NASDAQ: RNXT ) just reported results for the fourth quarter of 2023. RenovoRx reported earnings per share of -30 cents.

What type of business is RenovoRx?

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

What sector is RenovoRx in?

RenovoRx is in the Healthcare sector

What industry is RenovoRx in?

RenovoRx is in the Biotechnology industry

What country is RenovoRx from?

RenovoRx is headquartered in United States

When did RenovoRx go public?

RenovoRx initial public offering (IPO) was on 26 August 2021

What is RenovoRx website?

https://renovorx.com

Is RenovoRx in the S&P 500?

No, RenovoRx is not included in the S&P 500 index

Is RenovoRx in the NASDAQ 100?

No, RenovoRx is not included in the NASDAQ 100 index

Is RenovoRx in the Dow Jones?

No, RenovoRx is not included in the Dow Jones index

When was RenovoRx the previous earnings report?

No data

When does RenovoRx earnings report?

The next expected earnings date for RenovoRx is 09 May 2025